Followers | 245 |
Posts | 49722 |
Boards Moderated | 69 |
Alias Born | 08/29/2007 |
Tuesday, February 13, 2024 6:44:33 AM
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent ARCT News
- Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024 • Business Wire • 04/25/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:05:52 PM
- Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress • Business Wire • 03/07/2024 09:01:00 PM
- Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference • Business Wire • 02/26/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:05:35 PM
- Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis • Business Wire • 02/22/2024 01:30:00 PM
- Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024 • Business Wire • 02/20/2024 02:00:00 PM
- New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster • Business Wire • 02/05/2024 01:30:00 PM
- New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster • PR Newswire (US) • 02/05/2024 01:30:00 PM
- CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster • Business Wire • 12/21/2023 01:00:00 PM
- CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster • PR Newswire (US) • 12/21/2023 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 01:01:03 AM
- Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference • Business Wire • 12/04/2023 01:30:00 PM
- Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults • PR Newswire (US) • 11/28/2023 01:05:00 PM
- Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults • Business Wire • 11/28/2023 01:00:00 PM
- Arcturus Therapeutics Gets FDA Orphan Designation for ARCT-032 in Cystic Fibrosis • Dow Jones News • 11/27/2023 02:13:00 PM
- Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis • Business Wire • 11/27/2023 01:30:00 PM
- Keep An Eye Out: Pre-Market Movers And Analyst Recommendations • IH Market News • 11/15/2023 01:51:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:10:46 PM
- Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress • Business Wire • 11/14/2023 09:01:00 PM
- Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023 • Business Wire • 10/25/2023 08:01:00 PM
- Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences • Business Wire • 10/23/2023 08:01:00 PM
- Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government • Business Wire • 10/04/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2023 08:06:46 PM
- Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis • Business Wire • 09/26/2023 12:30:00 PM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM